Insight into approvals, marketing, and pricing of new medicines, 2018 to 2023 / Blake Wladyka and Étienne Gaudette = Aperçu des approbations, de la commercialisation et des prix des nouveaux médicaments,...: H82-66/2025-PDF
"High-cost specialty medicines are increasingly dominating the landscape of new medicines launched in Canada and around the world. A growing share of these medicines (including biologics, orphan drugs, and oncology products) have annual treatment costs in the tens or hundreds of thousands of dollars. This study provides an overview of new medicine approvals, sales, pricing, characteristics, and access in Canada and internationally"--Objective.
Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.965452&sl=0
| Department/Agency |
|
|---|---|
| Title | Insight into approvals, marketing, and pricing of new medicines, 2018 to 2023 / Blake Wladyka and Étienne Gaudette = Aperçu des approbations, de la commercialisation et des prix des nouveaux médicaments, de 2018 à 2023 / Blake Wladyka et Étienne Gaudette. |
| Variant title |
|
| Publication type | Monograph |
| Language | Bilingual-[English | French] |
| Format | Digital text |
| Electronic document | |
| Parallel description | [French] |
| Note(s) |
|
| Publishing information |
|
| Author / Contributor |
|
| Description | 1 online resource (1 page) : colour illustrations |
| Catalogue number |
|
| Subject terms |
Request alternate formats
To request an alternate format of a publication, complete the Government of Canada Publications email form. Use the form’s “question or comment” field to specify the requested publication.Page details
- Date modified: